Amazec Photonics, a Netherlands-based company specializing in integrated photonics for cardiovascular monitoring and diagnostics, has successfully raised €1.5M in a Seed funding round. The round was led by PhotonDelta, a cross-border growth accelerator and ecosystem for photonic chip technology organizations, with additional contributions from several private investors.
Laurens Weers, CFO of PhotonDelta, praised Amazec Photonics for its innovative use of photonics technology to create a device that could significantly impact global health. Cardiovascular disease, being a major health challenge, requires better diagnostics for saving lives, and Amazec Photonics is poised to become a key player in this field.
Advertisement
Addressing a Global Health Challenge
Amazec Photonics aims to tackle the challenge of cardiovascular diseases, which are responsible for 19 million deaths annually. The company’s solution offers early and accurate diagnosis at minimal cost and complexity, potentially saving millions of lives by improving the accuracy of cardiovascular disease testing.
Founding Team and Vision
Founded in 2021 by Pim Kat, Ton Backx, Erik Korsten, and Arthur Bouwman, Amazec Photonics is driven by the rising global prevalence of cardiovascular diseases. CEO Pim Kat highlighted the inadequacy of current diagnostic tools and the potential of Amazec’s solution to make a real difference by being less invasive, simpler to use, and substantially reducing costs.
Innovative Use of Photonics Technology
Amazec Photonics’ solution leverages photonics technology to achieve precision in measuring temperature changes, offering a significant improvement over conventional techniques. The external monitoring device eliminates the need for invasive procedures, enhancing reliability and patient outcomes.
Utilization of Capital
The funding will support the development of Amazec Photonics’ minimally invasive diagnostic devices for clinical trials. The company plans to build ten prototypes and undertake extensive clinical trials with the goal of producing and selling devices across the EU by 2028. Clinical trials of its device are set to commence at Catharina Hospital in Eindhoven this year, with plans to expand trials to three additional hospitals in 2025.
Enhancing Cardiac Monitoring
Amazec Photonics’ system, which builds on previous R&D projects, has improved the integrated photonics chip and developed new algorithms for processing raw data into meaningful signals. This innovation enables more reliable cardiac output measurements and introduces a new clinical parameter for measuring blood volume in the body.
With this funding, Amazec Photonics is on track to revolutionize cardiovascular monitoring and diagnostics, offering a new generation of photonics-based technology that could become a standard in medtech and significantly improve patient care.
